GenMark Diagnostics, Inc. (GNMK) Reaches $4.60 After 5.00% Down Move; Kona Grill (KONA) Has 0.25 Sentiment

January 14, 2018 - By Dolores Ford

The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) is a huge mover today! The stock decreased 2.75% or $0.13 during the last trading session, reaching $4.6. About 357,944 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has risen 116.11% since January 14, 2017 and is uptrending. It has outperformed by 99.41% the S&P500.The move comes after 6 months negative chart setup for the $252.06M company. It was reported on Jan, 14 by Barchart.com. We have $4.37 PT which if reached, will make NASDAQ:GNMK worth $12.60M less.

Kona Grill, Inc. owns and operates upscale casual restaurants under the Kona Grill brand name. The company has market cap of $18.19 million. As of August 15, 2017, it owned and operated 46 restaurants in 23 states of the United States and Puerto Rico; and 1 franchise restaurant in Monterrey, Mexico. It currently has negative earnings.

The stock increased 2.86% or $0.05 during the last trading session, reaching $1.8. About 46,142 shares traded. Kona Grill, Inc. (KONA) has declined 61.08% since January 14, 2017 and is downtrending. It has underperformed by 77.78% the S&P500.

Anson Funds Management Lp holds 0.5% of its portfolio in Kona Grill, Inc. for 875,574 shares. Bourgeon Capital Management Llc owns 15,000 shares or 0.03% of their US portfolio. Moreover, Brandywine Global Investment Management Llc has 0.02% invested in the company for 723,723 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of Montreal Can, a Ontario – Canada-based fund reported 1,660 shares.

Ratings analysis reveals 50% of Kona Grill’s analysts are positive. Out of 2 Wall Street analysts rating Kona Grill, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. KONA was included in 2 notes of analysts from September 29, 2016. As per Friday, October 28, the company rating was maintained by Wedbush. The stock has “Sector Weight” rating by KeyBanc Capital Markets on Thursday, September 29.

Investors sentiment decreased to 1.88 in 2017 Q3. Its down 2.12, from 4 in 2017Q2. It worsened, as 11 investors sold GenMark Diagnostics, Inc. shares while 15 reduced holdings. 11 funds opened positions while 38 raised stakes. 56.57 million shares or 46.84% less from 106.41 million shares in 2017Q2 were reported. Moreover, Bnp Paribas Arbitrage has 0% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Manufacturers Life Ins Communications The stated it has 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Cannell Peter B & Inc invested 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Raymond James Assoc owns 30,350 shares. Northern Trust owns 699,201 shares. Alliancebernstein Lp accumulated 49,300 shares. Blair William & Il holds 44,417 shares. American Gp holds 0% or 29,442 shares in its portfolio. California State Teachers Retirement reported 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Millennium Mgmt Limited Liability Corp accumulated 0.02% or 1.47 million shares. Barclays Public Ltd Company holds 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK) or 1,181 shares. Moreover, Tci Wealth Advisors has 0.03% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK). The Massachusetts-based Adage Cap Prtn Gru Ltd Liability Corporation has invested 0.02% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Moreover, Quantitative Systematic Strategies Limited Liability Corporation has 0.05% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 17,621 shares. Thrivent For Lutherans has 0.02% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK).

Among 6 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Genmark Diagnostics had 18 analyst reports since October 14, 2015 according to SRatingsIntel. The rating was upgraded by Cowen & Co on Friday, September 16 to “Outperform”. As per Wednesday, August 2, the company rating was maintained by Needham. Canaccord Genuity maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) rating on Monday, August 7. Canaccord Genuity has “Buy” rating and $1400 target. The firm has “Buy” rating by Canaccord Genuity given on Monday, October 30. Needham maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Wednesday, October 28 with “Buy” rating. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Monday, June 12 by Canaccord Genuity. The firm earned “Buy” rating on Wednesday, February 24 by Needham. Raymond James downgraded GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Friday, November 3 to “Market Perform” rating. Canaccord Genuity maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) rating on Friday, November 3. Canaccord Genuity has “Buy” rating and $10 target. The rating was maintained by Needham on Tuesday, January 24 with “Buy”.

Since August 2, 2017, it had 0 insider purchases, and 15 sales for $600,720 activity. Another trade for 341 shares valued at $3,523 was sold by Williams Jennifer Anne. Another trade for 333 shares valued at $3,440 was made by Mendel Scott on Wednesday, August 2. Another trade for 1,629 shares valued at $16,828 was made by MASSARANY HANY on Wednesday, August 2. $4,225 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) was sold by Gleeson Michael. Kayyem Jon Faiz sold $1,426 worth of stock or 138 shares. Shares for $3,874 were sold by Stier Eric on Wednesday, August 2.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $252.06 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: